Show
Sort by
-
Cusatuzumab for treatment of CD70-positive relapsed or refractory cutaneous T-cell lymphoma
-
Argx-110 for treatment of CD70-positive advanced cutaneous T-cell lymphoma in a phase 1/2 clinical trial
-
Phase I dose-escalation study of the anti-CD70 antibody ARGX-110 in advanced malignancies
-
Clinical response observed in a phase I study in T cell lymphoma patients treated with anti-CD70 SIMPLE antibody ARGX-110
-
ARGX-110, a highly potent antibody targeting CD70, eliminates tumors via both enhanced ADCC and immune checkpoint blockade
-
A phase I first-in-human study of ARGX-110, a monoclonal antibody targeting CD70, a receptor involved in immune escape and tumor growth in patients with solid and hematologic malignancies
-
Highly efficient peptide separations in proteomics Part 2: Bi- and multidimensional liquid-based separation techniques
(2009) JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES. 877(11-12). p.1019-1039 -
Highly efficient peptide separations in proteomics - Part 1. Unidimensional high performance liquid chromatography